TrialEuropean child & adolescent psychiatry2025

Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies.

Melissa P DelBello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.